The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 06, 2017

Filed:

Dec. 17, 2012
Applicant:

University of Zürich, Zürich, CH;

Inventors:

Roger Nitsch, Zumikon, CH;

Christoph Hock, Erlenbach, CH;

Christoph Esslinger, Zurich, CH;

Marlen Knobloch, Tolochenaz, CH;

Kathrin Tissot, Neuried, DE;

Jan Grimm, Duebendorf, CH;

Assignee:

UNIVERSITY OF ZURICH, Zurich, CH;

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/00 (2006.01); C07K 16/18 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); G01N 33/68 (2006.01); A61K 51/10 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/18 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61K 51/1018 (2013.01); C07K 16/00 (2013.01); G01N 33/6896 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/30 (2013.01); C07K 2317/34 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); G01N 2800/2821 (2013.01); G01N 2800/52 (2013.01);
Abstract

Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.


Find Patent Forward Citations

Loading…